Literature DB >> 8614526

Trinucleotide repeat length and clinical progression in Huntington's disease.

J Brandt1, F W Bylsma, R Gross, O C Stine, N Ranen, C A Ross.   

Abstract

We examined the relationship between length of the trinucleotide (CAG) repeat at IT-15 and clinical progression of Huntington's disease in 46 mildly to moderately affected patients over a 2-year interval. Patients were divided into those with short mutations (37 to 46 repeats; n = 25) and those with long mutations (> or = 47 repeats; n = 21). Patients with long repeat lengths had earlier age at onset and were younger and less functionally impaired than those with short repeats at the initial visit, but the groups did not differ in severity of neurologic or cognitive impairment. However, the long-repeat group displayed significantly greater decline in both neurologic and cognitive functioning over the 2-year follow-up period. The length of the CAG repeat correlated highly with age at onset (r = -0.72, p < 0.001) and was a strong predictor of decline in both neurologic and cognitive function. The mechanism of gene action, and the means by which longer expansions result in a more malignant disease process, remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8614526     DOI: 10.1212/wnl.46.2.527

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

Review 1.  Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics.

Authors:  Tiago A Mestre; Cristina Sampaio
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

Review 2.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

3.  Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.

Authors:  Paul G Unschuld; Richard A E Edden; Aaron Carass; Xinyang Liu; Megan Shanahan; Xin Wang; Kenichi Oishi; Jason Brandt; Susan S Bassett; Graham W Redgrave; Russell L Margolis; Peter C M van Zijl; Peter B Barker; Christopher A Ross
Journal:  Mov Disord       Date:  2012-05-30       Impact factor: 10.338

4.  Modeling Huntington's disease in cells, flies, and mice.

Authors:  S Sipione; E Cattaneo
Journal:  Mol Neurobiol       Date:  2001-02       Impact factor: 5.590

Review 5.  Brain imaging and cognitive dysfunctions in Huntington's disease.

Authors:  Alonso Montoya; Bruce H Price; Matthew Menear; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

6.  Differences in duration of Huntington's disease based on age at onset.

Authors:  T Foroud; J Gray; J Ivashina; P M Conneally
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

Review 7.  The genetic defect causing Huntington's disease: repeated in other contexts?

Authors:  J F Gusella; F Persichetti; M E MacDonald
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

8.  Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease.

Authors:  Paul G Unschuld; Suresh E Joel; Xinyang Liu; Megan Shanahan; Russell L Margolis; Kevin M Biglan; Susan S Bassett; David J Schretlen; Graham W Redgrave; Peter C M van Zijl; James J Pekar; Christopher A Ross
Journal:  Neurosci Lett       Date:  2012-03-07       Impact factor: 3.046

9.  Early onset Huntington disease: a neuronal degeneration syndrome.

Authors:  Sara Seneca; Domique Fagnart; Kathelijn Keymolen; Willy Lissens; Daniele Hasaerts; Sara Debulpaep; Brigitte Desprechins; Inge Liebaers; Linda De Meirleir
Journal:  Eur J Pediatr       Date:  2004-12       Impact factor: 3.183

Review 10.  Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease.

Authors:  Rodrigo A Quintanilla; Gail V W Johnson
Journal:  Brain Res Bull       Date:  2009-07-19       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.